Form 4: Sangamo Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, sold shares to cover tax obligations related to vested restricted stock units.
Summary
- On April 22, 2025, Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, sold 31,866 shares of common stock at a price of $0.7763 per share to cover tax obligations.
- The sale was related to the vesting of a portion of a restricted stock unit (RSU) grant.
- Following the transaction, Willoughby directly owns 782,976 shares of Sangamo Therapeutics common stock.
- These shares include those from previous RSU grants that are vesting in quarterly installments through February 24, 2026, and February 25, 2028.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction for tax purposes, with no inherent positive or negative implications for the company's prospects.
Future Outlook
The reporting person's remaining RSU grants will continue to vest in quarterly installments through January 22, 2026, February 24, 2026, and February 25, 2028, subject to continued service.
Industry Context
Form 4 filings are routine disclosures of insider transactions and are a normal part of corporate governance. This particular filing reflects the standard practice of executives selling shares to cover tax obligations arising from the vesting of equity compensation.
Comparison to Industry Standards
- Equity compensation and subsequent tax-related sales are common practices among executives in publicly traded companies, particularly in the biotechnology sector.
- Companies like CRISPR Therapeutics and Editas Medicine also utilize RSU grants as part of their compensation packages, and their executives likely engage in similar transactions to manage tax liabilities.
- The vesting schedules and terms of the RSU grants are generally aligned with industry standards for incentivizing long-term performance and retention.
Stakeholder Impact
- The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
- The transaction does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| January 22, 2024 | Date of RSU grant, vesting in quarterly installments through January 22, 2026 |
| February 24, 2023 | Date of RSU grant, vesting in quarterly installments through February 24, 2026 |
| February 25, 2025 | Date of RSU grant, vesting as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter |
| April 22, 2025 | Date of transaction: Sale of 31,866 shares for tax withholding; vesting of RSU installment |
| April 24, 2025 | Date of Form 4 filing |
| February 25, 2026 | One-fourth (1/4) of the shares from the February 25, 2025 RSU grant will vest |
| February 25, 2028 | Final vesting date for shares from the February 25, 2025 RSU grant |
Keywords
Form 4, Sangamo Therapeutics, SGMO, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Scott B. Willoughby, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.